EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Bivalent mRNA‐LNP Vaccine for Highly Effective Protection against Pneumonic Plague

Uri Elia iD, Yinon Levy, Hila Cohen, Ayelet Zauberman iD, David Gur, Inbal Hazan-Halevy iD, Moshe Aftalion, Shani Benarroch, Erez Bar-Haim iD, Orit Redy-Keisar iD, Ofer Cohen iD, Dan Peer iD und 1 weitere

Advanced Science · 2025-07 · 12 (26)

DOI: 10.1002/advs.202501286 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 25.04.2025. Verfasst von Uri Elia und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona, 76100, Israel. Hauptthemen laut MEDLINE: Plague, Yersinia pestis, Plague Vaccine, RNA, Messenger. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's Horizon 2020 research and innovation program, Israel Institute for Biological Research, European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Yersinia pestis , the causative agent of plague, remains a significant global health hazard and a potential top‐tier biothreat despite modern medical advances. Here, two mRNA constructs encoding different versions of the low‐calcium response virulence (LcrV) protective antigen, an essential virulence factor of Y. pestis , are designed and evaluated. Next, the immunogenicity and protective efficacy both independently and in combination is assessed with the previously reported F1‐encoding mRNA construct in the well‐established mouse model of pneumonic plague. The findings reveal that human Fc‐conjugated F1 + LcrV combination mRNA vaccination resulted in significant immune activation and substantial protection against intranasal Y. pestis challenge. Notably, the combined vaccine demonstrates protective efficacy against two highly virulent wild‐type Y. pestis strains representing distinct biovars and an atypical, unencapsulated strain. This study represents the first comprehensive evaluation of mRNA constructs encoding innovatively designed versions of LcrV and F1 for pneumonic plague prevention, addressing critical gaps in current vaccination approaches. This study establishes the mRNA‐lipid nanoparticle (LNP) platform as a promising tool for addressing bacterial pathogens, including those resistant to antibiotics. By broadening its applicability to diverse threats, this technology represents an innovative approach to tackling some of the most pressing challenges in global health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PlagueYersinia pestisPlague VaccineRNA, MessengerNanoparticlesAnimalsMicePore Forming Cytotoxic ProteinsAntigens, BacterialFemaleDisease Models, AnimalMice, Inbred BALB CHumansBacterial ProteinsLiposomes

Stichwörter der Autor:innen

Y. pestislipid nanoparticlesmRNAvaccine

Substanzen

Plague VaccineRNA, MessengerPore Forming Cytotoxic ProteinsAntigens, BacterialLcrV protein, YersiniaLipid NanoparticlesBacterial ProteinsLiposomes

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona, 76100, Israel.
  • Laboratory of Precision NanoMedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, 69978, Israel.
  • Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv, 69978, Israel.
  • Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv, 69978, Israel.
  • Cancer Biology Research Center, Tel Aviv University, Tel Aviv, 69978, Israel.
  • Department of Organic Chemistry, Israel Institute for Biological Research, Ness-Ziona, 76100, Israel.

ORCID-Profile: Uri Elia, Ayelet Zauberman, Inbal Hazan-Halevy, Erez Bar-Haim, Orit Redy-Keisar, Ofer Cohen, Dan Peer, Emanuelle Mamroud

Förderung

  • European Union's Horizon 2020 research and innovation program
  • Israel Institute for Biological Research
  • European Research Council

Zitieren

APA

Elia, U., Levy, Y., Cohen, H., Zauberman, A., Gur, D., Hazan-Halevy, I., Aftalion, M., Benarroch, S., Bar-Haim, E., Redy-Keisar, O., Cohen, O., Peer, D., & Mamroud, E. (2025). Novel Bivalent mRNA‐LNP Vaccine for Highly Effective Protection against Pneumonic Plague. Advanced Science, 12(26). https://doi.org/10.1002/advs.202501286

Vancouver

Elia U, Levy Y, Cohen H, Zauberman A, Gur D, Hazan-Halevy I, et al. Novel Bivalent mRNA‐LNP Vaccine for Highly Effective Protection against Pneumonic Plague. Advanced Science. 2025;12(26). doi:10.1002/advs.202501286

BibTeX
@article{Elia2025,
  author = {Elia, Uri and Levy, Yinon and Cohen, Hila and Zauberman, Ayelet and Gur, David and Hazan-Halevy, Inbal and Aftalion, Moshe and Benarroch, Shani and Bar-Haim, Erez and Redy-Keisar, Orit and Cohen, Ofer and Peer, Dan and Mamroud, Emanuelle},
  title = {Novel Bivalent mRNA‐LNP Vaccine for Highly Effective Protection against Pneumonic Plague},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {26},
  doi = {10.1002/advs.202501286}
}
Kostenlos starten →